The effects of cranberry on glucose levels and HbA1C with type 2 diabetes patients- a randomized clinical trial

Diabetes mellitus is a common endocrine disorder that affects 100 million people annually. It is considered as an important risk factor for clinical disorders such as nephropathy, neuropathy, retinopathy and cardiovascular diseases. The aim of this study was to examine the effects of cranberry (Cornus mas L.) on blood glucose and HbA1C levels in patients with type 2 diabetes. This randomized clinical trial, double-blind, placebo-controlled performed in the period of 6 weeks. 60 patients aged 41-65 years with diabetes participated in the study. Patients were randomly divided into control, consumer capsule placebo (n= 30) and group use, Cornus mas capsules. At the beginning and end of the study, fasting blood sugar (FBS), and glycosylated hemoglobin (HbA1c) were measured using t-test and ANCOVA. There was no significant difference between the groups at baseline about the characteristics of the subjects (FBS, HbA1c, age). Cornus mas group compared with the control group receiving at the end of 6 weeks, the factors FBS and HbA1c decreased significantly (P< 0.05). Reducing FBS and HbA1c in patients with diabetes consumed Cornus mas for control is valuable. These changes in fasting blood glucose and glycosylated hemoglobin levels may be the result of anthocyanin compounds in the level of Cornus mas.